This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Veracyte Announces Appointment Of Shelly D. Guyer As Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., April 12, 2013 /PRNewswire/ --  Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Shelly D. Guyer as chief financial officer.

"We are delighted to welcome Shelly Guyer to the Veracyte team," said Bonnie Anderson, Veracyte's cofounder and chief executive officer. "Her extensive background in the life science and finance industries will be critical as we experience strong growth of our first product, the Afirma® Thyroid FNA Analysis, and as we expand our molecular cytology platform to other clinical areas to similarly help reduce unnecessary surgeries and lower healthcare costs." Ms. Anderson noted that data published in the New England Journal of Medicine suggest that Veracyte's genomic test for improved thyroid cancer diagnosis can potentially help tens of thousands of patients each year in the United States avoid thyroid surgery.

Ms. Guyer previously was chief financial officer and executive vice president of finance and administration at iRhythm Technologies, a private, venture-backed medical device and services company. Prior to that, she served on the management team and as vice president of business development and investor relations at Nuvelo, a public biotechnology company. Ms. Guyer began her business career at J.P. Morgan Securities and its predecessor companies, where for over 17 years she held various positions, including principal and vice president of health care banking for the West Coast, leading financings for a variety of large and small cap life science companies.

"I am pleased to join the talented management team at Veracyte," said Ms. Guyer. "The company's mission of helping patients avoid surgery is compelling. Additionally, with the introduction of its first product, the Afirma Thyroid FNA Analysis, Veracyte has set a new standard for launching a molecular diagnostics product successfully, quickly and cost-efficiently. I look forward to helping the company build on its success to date."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,723.55 +251.18 1.52%
S&P 500 1,981.76 +30.40 1.56%
NASDAQ 4,767.00 +59.2250 1.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs